How to buy Ionis Pharmaceuticals stock (IONS)

Ionis Pharmaceuticals is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $39.71 – an increase of 3.36% over the previous week. Ionis Pharmaceuticals employs 927 staff and has a trailing 12-month revenue of around $813.5 million.

Our top picks for where to buy Ionis Pharmaceuticals stock

Buy Ionis Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ionis Pharmaceuticals stock price (NASDAQ: IONS)

Use our graph to track the performance of IONS stocks over time.

Ionis Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$39.71
52-week range	$35.95 - $54.44
50-day moving average more info button	$42.56
200-day moving average more info button	$44.25
Wall St. target price	$61.72
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.52

Is it a good time to buy Ionis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ionis Pharmaceuticals price performance over time

Historical closes compared with the close of $40.36 from 2024-10-28

1 week (2024-10-22)	4.34%
1 month (2024-09-30)	0.75%
3 months (2024-07-30)	-18.92%
6 months (2024-04-30)	-2.18%

1 year (2023-10-30)	-8.27%
2 years (2022-10-26)	-9.00%
3 years (2021-10-29)	26.64%
5 years (2019-10-30)	56.72

Is Ionis Pharmaceuticals stock undervalued or overvalued?

Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ionis Pharmaceuticals's PEG ratio

Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Ionis Pharmaceuticals financials

Revenue TTM	$813.5 million
Gross profit TTM	$-257,866,000
Return on assets TTM	-7.58%
Return on equity TTM	-105.71%
Profit margin	-44.96%
Book value	$1.81
Market Capitalization more info button	$6.1 billion

TTM: trailing 12 months

Ionis Pharmaceuticals share dividends

We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.

Ionis Pharmaceuticals share price volatility

Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $35.95 up to $54.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 0.384. This would suggest that Ionis Pharmaceuticals's shares are less volatile than average (for this exchange).

Ionis Pharmaceuticals overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Frequently asked questions

What percentage of Ionis Pharmaceuticals is owned by insiders or institutions?
Currently 0.781% of Ionis Pharmaceuticals shares are held by insiders and 98.093% by institutions. How many people work for Ionis Pharmaceuticals?
Latest data suggests 927 work at Ionis Pharmaceuticals. When does the fiscal year end for Ionis Pharmaceuticals?
Ionis Pharmaceuticals's fiscal year ends in December. Where is Ionis Pharmaceuticals based?
Ionis Pharmaceuticals's address is: 2855 Gazelle Court, Carlsbad, CA, United States, 92010 What is Ionis Pharmaceuticals's ISIN number?
Ionis Pharmaceuticals's international securities identification number is: US4622221004 What is Ionis Pharmaceuticals's CUSIP number?
Ionis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 462222100